CJC-1295 with DAC vs Thymosin Beta-4
Well Studied vs Well Studied
synergistic Mechanism-based · 47% CJC-1295 with DAC and Thymosin Beta-4 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 with DAC Thymosin Beta-4
Weight 3,647.28 Da 4,963.44 Da
Half-life 6-8 days Dose-dependent; relatively short (exact values not established)
Chain 30 amino acids 43 amino acids
Type GHRH analog with DAC Thymosin peptide
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Thymosin Beta-4
01 Systemic regenerative effects
02 Proven clinical efficacy
03 Optimal bioavailability for tissue repair
04 Promotes angiogenesis
05 Reduces inflammation
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Thymosin Beta-4
2-6mg per injection (varies by protocol and severity) / Daily for acute healing, 2x weekly for maintenance/chronic conditions
Acute Wound Healing 1.6mg Daily
Cardiac Protection 42mg Single dose
Chronic Tissue Repair 6mg Twice weekly
Neurological Recovery 30mg Three times over 72 hours
General Regeneration 2-5mg Daily or every other day
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Thymosin Beta-4
Mild injection site reactions
Local inflammation at injection sites
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Active chemotherapy treatment
Severe systemic allergies to peptides
Research Evidence
CJC-1295 with DAC Thymosin Beta-4
Status Well Studied Well Studied
References 4 studies 4 studies
Latest 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.